Health Trials

Gynecologycal Cancer

2

Review clinical trials related to Gynecologycal Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.

Participants needed: 30
Trial details
Age: 50+Biological sex: FemaleType: ObservationalSponsor: Wake Forest University Health SciencesUpdated: Jul 30, 2026Locations: 2
Eligibility criteria

Ability to understand and willingness to sign an IRB-approved informed consent [+4]

Previously treated for ovarian or endometrial cancer [+3]

Read more
Status: Recruiting

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

The goal of this study is listed below. Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%. Part B (Randomization Phase) : To evaluate the efficacy of pembrolizumab and nesuparib combination/ pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.

Participants needed: 92
Trial details
Phase: Phase 2Age: 19+Biological sex: FemaleType: InterventionalSponsor: Yonsei UniversityUpdated: Apr 3, 2025Locations: 6
Eligibility criteria

Patient must be female ≥ 19 years of age [+19]

Patient has undergone prior treatment with a known PARP inhibitor. [+23]

Read more